What is the Global AI in Medical Imaging Horizon report?

The Global AI in Medical Imaging Horizon: Forecasts, Competitive Architecture, and Reimbursement-Driven Monetization, 2024A–2035E is a Marketstrat report analyzing how artificial intelligence is being commercialized across medical imaging. It covers AI-attributable revenue across modalities, clinical applications, technology layers, revenue streams, end users, geographies, and reimbursement tiers. The report is designed to help executives, investors, imaging vendors, AI companies, and provider organizations understand where AI imaging value is forming and who is positioned to capture it.

What is included in the AI in medical imaging market forecast?

The report includes a global 2024A–2035E forecast for the AI in medical imaging market, with segmentation by modality, clinical area, application, technology layer, revenue stream, end-user organization, geography, and reimbursement tier. Covered areas include CT AI, MRI AI, X-ray / digital radiography AI, mammography AI, ultrasound AI, nuclear / PET AI, oncology imaging AI, cardiology imaging AI, neurology imaging AI, workflow orchestration, image reconstruction, quantification, reporting, cloud / pay-per-use AI, and enterprise software monetization. The base-case model estimates the global AI medical imaging market at approximately $3.8B in 2024A and $33.6B by 2035E.

How is this report different from other radiology AI or medical imaging AI reports?

Many AI imaging reports focus on regulatory clearances, vendor lists, or broad technology adoption. This report focuses on monetization architecture: how AI imaging products generate revenue, how reimbursement changes adoption and pricing, how workflow control affects vendor defensibility, and how enterprise deployment changes the competitive landscape. The analysis treats AI in medical imaging as more than a collection of algorithms. It examines the market as a set of commercial control points across scanners, PACS, enterprise imaging, reporting, cloud infrastructure, provider networks, reimbursement pathways, and clinical workflow.

Why is reimbursement important in the AI medical imaging market?

Reimbursement is becoming one of the most important dividing lines in the AI medical imaging market. AI tools that support reimbursed or premium clinical outputs can monetize differently from tools that rely mainly on productivity savings, scanner attach, enterprise software budgets, or general workflow ROI. The report introduces a reimbursement-tier framework to distinguish mature reimbursed AI, developing reimbursement categories, non-reimbursed productivity AI, and hardware-embedded or out-of-tier AI. This lens helps explain why some AI imaging categories scale faster, command stronger pricing, or become more attractive to strategic buyers.

Which companies and competitive groups are analyzed in the report?

The report analyzes the competitive landscape across imaging OEMs, enterprise imaging vendors, PACS / RIS / VNA platforms, AI-native clinical platforms, reimbursed analytics specialists, breast and oncology AI vendors, reconstruction and acquisition AI vendors, reporting and workflow automation companies, AI orchestration and governance platforms, cloud infrastructure providers, and provider-network AI platforms. The report discusses major participants and ecosystem signals across companies such as GE HealthCare, Siemens Healthineers, Philips, Canon Medical, Fujifilm, United Imaging, Pro Medicus, Sectra, Intelerad, Aidoc, Viz.ai, RapidAI, Qure.ai, Annalise.ai, DeepHealth / RadNet, HeartFlow, Cleerly, Lunit, iCAD, ScreenPoint, Hologic, Rad AI, Microsoft / Nuance, deepc, CARPL.ai, Ferrum Health, AWS, Microsoft Azure, Google Cloud, NVIDIA, and others.

Who should use this AI in medical imaging market report?

This report is intended for imaging OEM executives, AI-native medical imaging vendors, PACS and enterprise imaging companies, radiology groups, imaging center operators, teleradiology providers, health-system leaders, cloud and infrastructure providers, investors, corporate development teams, investment banks, private equity firms, venture capital investors, reimbursement strategists, and product / commercial leaders. It is designed to support market-entry decisions, product strategy, M&A screening, competitive positioning, partnership planning, reimbursement strategy, and long-range market forecasting in the global AI medical imaging market.

Global AI in Medical Imaging Horizon: Forecasts, Competitive Architecture, and Reimbursement-Driven Monetization, 2024A–2035E

Global AI in Medical Imaging Horizon: Forecasts, Competitive Architecture, and Reimbursement-Driven Monetization, 2024A–2035E - June 2026

Artificial intelligence is no longer a side theme in medical imaging. It is becoming a monetization layer across scanners, PACS, enterprise imaging, reporting, quantitative analytics, teleradiology, outpatient imaging networks, and cloud-based clinical workflow. The question is no longer simply which AI tools have regulatory clearance. The more important questions are: which tools get paid, which tools fit into clinical workflow, which vendors control distribution, and which business models can scale beyond pilots.

Marketstrat’s Global AI in Medical Imaging Horizon provides a 2024A–2035E view of this transition. The report sizes the global AI medical imaging market, segments it by modality, clinical area, application, technology layer, revenue stream, end-user group, geography, and reimbursement maturity, and explains how competitive advantage is shifting from narrow algorithms toward workflow, evidence, reimbursement documentation, enterprise deployment, and recurring software economics.

The base-case model places the global AI medical imaging market at approximately $3.8B in 2024A and $33.6B by 2035E, but the report is not just a sizing exercise. It is a market-structure, monetization, and competitive-architecture report built to help executives, investors, strategists, and commercial teams understand where AI imaging value is forming — and where it is likely to be captured. The report’s scope boundary is AI-attributable revenue across detection, workflow, reconstruction, quantification, and reporting, with hardware-embedded AI, cloud/pay-per-use, and services treated as distinct revenue streams.

Market Snapshot

The report is built around a reconciled 2024A–2035E market model and covers the major commercial dimensions of medical imaging AI: modality, clinical area, clinical application, technology layer, revenue stream, end-user organization, geography, and reimbursement tier. The base-case forecast places the global AI medical imaging market at approximately $3.8B in 2024A and approximately $33.6B by 2035E, with growth shaped by reimbursement expansion, enterprise platform adoption, AI-enabled productivity, cloud deployment, and disease-specific quantitative analytics.

Key Market Trends

The market is shifting from algorithms to monetization architecture.
The core thesis of the report is that AI imaging value is moving away from stand-alone algorithm novelty and toward workflow control, reimbursement readiness, enterprise deployment, and recurring revenue architecture. Regulatory clearance enables market entry, but it does not guarantee adoption or payment.
Reimbursement is now central to market segmentation.
The report introduces a reimbursement-tier lens to separate mature reimbursed AI, developing reimbursement categories, non-reimbursed productivity AI, and hardware-embedded / out-of-tier AI. This distinction is critical because reimbursed clinical outputs can support different pricing, evidence, documentation, and GTM models than general-purpose productivity tools.
The market remains high-growth, but the easy-growth assumption is gone.
AI medical imaging remains one of the highest-growth software and workflow layers in medical technology. However, growth is no longer assumed to be unlimited. The report’s base-case model shows strong expansion through 2030, followed by more disciplined growth as reimbursement, enterprise adoption, pricing normalization, and platform consolidation become gating variables.
Hardware-embedded AI remains large, but software, services, and cloud gain strategic weight.
Scanner-native AI remains important, especially in reconstruction, acquisition, protocol automation, dose reduction, and OEM clinical suites. But the value mix shifts toward enterprise software, cloud / pay-per-use, managed services, governance, and workflow control.
Oncology, cardiology, and neurology become the major disease-specific intelligence markets.
The report does not treat medical imaging AI as a single radiology category. It analyzes disease-specific value pools across oncology, cardiology, neurology, pulmonary, MSK, and multispecialty workflows. By 2035E, oncology, cardiology, and neurology account for roughly 70% of modeled AI imaging value.
Competitive advantage is concentrating around control points.
The strongest competitive positions are held by companies that control a deployment surface, reimbursement pathway, evidence file, workflow layer, or enterprise relationship.

Competitive Landscape

The AI medical imaging competitive landscape is consolidating around workflow control, enterprise integration, reimbursement leverage, and platform-scale distribution. The market is no longer best described as a fragmented population of algorithm developers. It is becoming a layered competitive system in which OEMs, enterprise imaging vendors, AI-native platforms, specialty analytics companies, cloud providers, and provider networks are all competing to control the deployment surface.

The report analyzes the competitive landscape across the major AI imaging control points, including imaging OEMs, enterprise imaging vendors, PACS / RIS / VNA platforms, AI-native clinical platforms, reimbursed quantitative analytics companies, breast and oncology AI vendors, reconstruction and acquisition AI companies, reporting and workflow automation vendors, AI orchestration / governance platforms, cloud infrastructure providers, and provider-network AI platforms.

Companies discussed include GE HealthCare, Siemens Healthineers, Philips, Canon Medical, Fujifilm, United Imaging, Pro Medicus, Sectra, Intelerad, AGFA HealthCare, Aidoc, Viz.ai, RapidAI, Qure.ai, Annalise.ai, DeepHealth / RadNet, HeartFlow, Cleerly, Elucid, Circle Cardiovascular Imaging, Lunit, iCAD, ScreenPoint, Hologic, Vara, Rad AI, Microsoft / Nuance, deepc, CARPL.ai, Ferrum Health, Blackford, Incepto, AWS, Microsoft Azure, Google Cloud, NVIDIA, and others.

Key Questions Answered

Market size and forecast architecture

How large is the global AI in medical imaging market today, and how does Marketstrat expect it to evolve through 2035E?
How should investors and executives interpret TAM, SAM, and expected captured market in a category where hardware-embedded AI, enterprise software, services, cloud inference, and reimbursed analytics overlap?
Where does growth accelerate through 2030, and where does the market begin to mature after 2030?

Monetization and business model

Which AI imaging revenue streams are most defensible: hardware-embedded AI, enterprise software, services, or cloud / pay-per-use?
How does reimbursement change the commercial model for cardiac CT, mammography, quantitative analytics, and other evidence-backed use cases?
Which AI categories are likely to monetize through direct payment, and which must rely on productivity ROI, workflow savings, or scanner attach?

Clinical and modality opportunity

Which modalities are most attractive for AI monetization: CT, MRI, X-ray / digital radiography, mammography / DBT, ultrasound, or nuclear / PET?
Why does CT remain the near-term reimbursement anchor while MRI becomes a major long-run modality value pool?
Which clinical areas concentrate the largest value: oncology, cardiology, neurology, respiratory / pulmonary, MSK, or multispecialty AI?

Competitive architecture

Who controls the AI imaging value chain: OEMs, enterprise imaging vendors, PACS platforms, AI-native clinical platforms, reimbursed analytics specialists, provider networks, or cloud infrastructure companies?
How are major deal signals changing the competitive map?
Which vendor types are best positioned as the market shifts from stand-alone algorithms to workflow-embedded, reimbursed, and enterprise-managed AI?

What's Inside

The report covers the global market for AI-attributable revenue across medical imaging, including:

global market forecast, 2024A–2035E
TAM / SAM / expected captured market framing
base, bull, bear, and tail-risk scenarios
forecast sensitivity analysis
regional and country-level monetization logic
segmentation by modality, clinical area, clinical application, revenue stream, technology layer, end user, and reimbursement tier
competitive architecture across OEMs, enterprise imaging, PACS, AI-native platforms, reimbursed analytics, provider networks, and cloud infrastructure
FDA, De Novo, Breakthrough Device, PCCP, CMS / AMA CPT, payer evidence, EU AI Act / MDR, NMPA, PMDA / NHI, and other regulatory / reimbursement dynamics
stakeholder-specific implications for OEMs, AI-native vendors, enterprise imaging vendors, providers, investors, and strategic buyers

Why This Report?

The AI imaging market has entered a new phase. Between 2020 and 2024, much of the market narrative focused on FDA clearance counts, stand-alone detection algorithms, and radiology productivity. By 2026, the commercial conversation has changed.

Five changes now define the market:

Reimbursement is becoming a segmentation layer. AI that can produce billable or premium clinical outputs behaves differently from AI that must monetize through productivity, scanner attach, or enterprise software budgets.
Workflow control matters more than algorithm count. Vendors that sit inside the worklist, viewer, report, scanner, PACS, RIS, EHR, or care-pathway handoff have stronger renewal and distribution leverage than vendors selling isolated tools.
Quantification and reporting are emerging as high-value application layers. Detection remains important, but value is moving toward outputs that can be measured, trended, documented, billed, and tied to clinical decisions.
Foundation-model and multi-condition platforms are compressing single-indication vendors. Broad AI architectures can reduce the need for dozens of narrow algorithms, changing both product strategy and competitive defensibility.
Provider networks and enterprise imaging platforms are becoming AI control points. Radiology groups, outpatient imaging chains, teleradiology networks, PACS vendors, OEMs, cloud infrastructure providers, and AI-native platforms are increasingly competing for the same workflow surface.

Intended audience

This report is designed for decision-makers with exposure to medical imaging AI, including:

imaging OEM executives across strategy, product, informatics, services, and corporate development
AI-native imaging vendors and clinical workflow platforms
PACS, RIS, VNA, enterprise imaging, and reporting vendors
cloud, infrastructure, and AI governance providers
hospitals, IDNs, radiology groups, imaging centers, and teleradiology networks
payers, reimbursement strategists, and evidence-generation teams
private equity, venture capital, corporate development, investment banking, and public-market investors
medtech strategists, product leaders, GTM teams, and partnership teams

Report Details

Publisher: Marketstrat®
Series: Markintel® Horizon Report
Publication: June 2026
Report ID: MINTH-D01101-26A
Forecast period: 2024A–2035E
Length: 300+ pages
Tables / figures: 140+ tables and 70+ figures / frameworks
Geographic coverage: Global, North America, Europe, APAC, LATAM, MEA, and major country markets